



5.1.2e

---

**From:** 5.1.2e <5.1.2e@rivm.nl>  
**Sent:** 24 February 2021 01:59 PM  
**To:** 5.1.5 <5.1.2e@ecdc.europa.eu>  
**Subject:** RE: PREFINAL

**EXTERNAL EMAIL** - Do not click on any links, open attachments or reply, unless you recognise the sender's email address (5.1.2e@rivm.nl) and believe the content is safe.

---

Hi 5.1.2e

I had wanted to have it finished when I'd answer you, but you beat me to it \*. I'm working on it and plan to return the last edits today.

Groeten, 5.1.2e

---

**From:** EUROSURVEILLANCE <5.1.2e@ecdc.europa.eu>  
**Sent:** woensdag 24 februari 2021 13:56  
**To:** 5.1.2e <5.1.2e@rivm.nl>  
**Subject:** RE: PREFINAL

Dear Dr 5.1.2e

A gentle check-in to see if you will be able to send back the next version this afternoon so that I may provide you with the final for approval to circulate to your co-authors?

I would appreciate an update at your earliest convenience so that we may still meet our target of publishing tomorrow.

Kind regards,

5.1.2e



**Eurosurveillance**  
**Published by European Centre for Disease Prevention and Control (ECDC)**  
Gustav III:s boulevard 40, 169 73 Solna, Sweden  
Phone +46 (0)8 5.1.2e / Fax +46 5.1.2e  
[www.eurosurveillance.org](http://www.eurosurveillance.org)

Follow Eurosurveillance  
on:



---

**From:** EUROSURVEILLANCE  
**Sent:** 24 February 2021 10:24 AM  
**To:** 5.1.2e <5.1.2e@rivm.nl>  
**Subject:** PREFINAL

Dear Dr 5.1.2e

Thank you for your diligent work on the manuscript.

Please find attached the PREFINAL version of your manuscript with some minor queries and revised figures 1 and 2. If you can get back to me at your earliest convenience I can prepare a FINAL FOR APPROVAL version (not this one, but the next once you send this back) straight away so that you can start collecting approvals from your co-authors. Can you please confirm receipt of this email and let me know when you anticipate you will be able to return this to me so I can plan accordingly?

Further, can you please double check that the second attached document is the correct version of the supplement you would like us to publish and is the only supplementary material? There appears to be a supplement 2 for you, but in an unopenable file format.

Take care,

5.1.2e

#### Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan Informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.  
[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

[www.rivm.nl/en](http://www.rivm.nl/en) Committed to *health and sustainability*

#### Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.